Mechanism of action of lenalidomide in hematological malignancies

Mechanism of action of lenalidomide in hematological malignancies

<p>Abstract</p> <p>Immunomodulatory drugs lenalidomide and pomalidomide are synthetic compounds derived by modifying the chemical structure of thalidomide to improve its potency and reduce its side effects. Lenalidomide is a 4-amino-glutamyl analogue of thalidomide that lacks the n...

Full description

Bibliographic Details
Main Authors:	Kotla Venumadhav, Goel Swati, Nischal Sangeeta, Heuck Christoph, Vivek Kumar, Das Bhaskar, Verma Amit
Format:	Article
Language:	English
Published:	BMC 2009-08-01
Series:	Journal of Hematology & Oncology
Online Access:	http://www.jhoonline.org/content/2/1/36

Similar Items

Expanding role of lenalidomide in hematologic malignancies
by: Ghosh N, et al.
Published: (2015-05-01)

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
by: Zaiwei Song, et al.
Published: (2022-06-01)

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q
by: Isaac Park, et al.
Published: (2021-10-01)

Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
by: Yi Zhang, et al.
Published: (2023-01-01)

Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
by: Bernadene Fernandopulle, et al.
Published: (2010-05-01)

Eponyms in Malignant Hematology
by: Danielle Brazel, et al.
Published: (2022-01-01)

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma
by: C. Cerchione, et al.
Published: (2020-10-01)

Long-term hematological response in 5q- syndrome after lenalidomide suspension and further improvement by deferasirox.
by: Pasquale Niscola
Published: (2014-08-01)

A case of scleromyxedema responding to lenalidomide and dexamethasone
by: Sweta Rambhia, et al.
Published: (2017-01-01)

Arginase: Mechanisms and Clinical Application in Hematologic Malignancy
by: Zefan Du, et al.
Published: (2022-06-01)

Risk Factors and Environmental Preventive Actions for Aspergillosis in Patients with Hematological Malignancies
by: Daniel Raposo Puglia, et al.
Published: (2024-02-01)

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies
by: Yutong Xie, et al.
Published: (2022-07-01)

Molecular Mechanisms of Ferroptosis and Its Roles in Hematologic Malignancies
by: Yan Zhao, et al.
Published: (2021-10-01)

Advances in malignant hematology /
by: Saba, Hussain I. 536043, et al.
Published: (2011)

Autophagy in Hematological Malignancies
by: Olga García Ruiz, et al.
Published: (2022-10-01)

Candidiasis in hematologic malignancies
by: V. B. Larionova, et al.
Published: (2022-11-01)

Myeloid hematological malignancies
by: D. A. Domninsky
Published: (2014-07-01)

Lymphoid hematological malignancies
by: D. A. Domninskiy
Published: (2014-07-01)

Lymphoid hematological malignancies
by: D. A. Domninskiy
Published: (2014-07-01)

Myeloid hematological malignancies
by: D. A. Domninsky
Published: (2014-07-01)

Carbamazepine and Hematological Malignancies
by: İrfan Yavaşoğlu, et al.
Published: (2013-12-01)

Neoantigens in Hematologic Malignancies
by: Melinda A. Biernacki, et al.
Published: (2020-02-01)

Deubiquitinases in hematological malignancies
by: Hu Lei, et al.
Published: (2021-08-01)

Cell cycle regulation and hematologic malignancies
by: Yun Dai, et al.
Published: (2019-08-01)

Inflammation as a driver of hematological malignancies
by: Sumedha Saluja, et al.
Published: (2024-03-01)

Molecular Aspects of Hematological Malignancies and Benign Hematological Disorders
by: Amelia Maria Găman
Published: (2023-06-01)

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies
by: Hermann Einsele, et al.
Published: (2020-08-01)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
by: Cirino Botta, et al.
Published: (2021-04-01)

Centrosome Defects in Hematological Malignancies: Molecular Mechanisms and Therapeutic Insights
by: Mingzheng Hu, et al.
Published: (2022-07-01)

Lenalidomide-Induced Pure Red Cell Aplasia
by: Tuphan Kanti Dolai, et al.
Published: (2014-02-01)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
by: Sugimoto Yuka, et al.
Published: (2012-03-01)

Flow cytometry of hematological malignancies /
by: Ortolani, Claudio
Published: (2011)

Hematologic malignancies : myelodysplastic syndromes /
by: Deeg, H. Joachim (Hans Joachim), 1945-
Published: (2006)

Genomic Stratification of Hematological Malignancies
by: Pauline Robbe, et al.
Published: (2023-06-01)

Chromosome Territories in Hematological Malignancies
by: Matheus Fabiao de Lima, et al.
Published: (2022-04-01)

Immune Therapies for Hematologic Malignancies
by: Matthew J. Olnes
Published: (2021-01-01)

Mitochondrial transfer in hematological malignancies
by: Xiaodong Guo, et al.
Published: (2023-10-01)

Drug Resistance in Hematological Malignancies
by: Patrick Auberger, et al.
Published: (2020-08-01)

Intestinal Microbes and Hematological Malignancies
by: Yinghong Zhu, et al.
Published: (2023-04-01)

HMGA Proteins in Hematological Malignancies
by: Angela Minervini, et al.
Published: (2020-06-01)